MIB-1 (KI-67) Proliferation Index and Cyclin-Dependent Kinase Inhibitor p27Kip1 Protein Expression in Nephroblastoma

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 591-597

  Ghanem, Mazen A ^a,c   Van Der Kwast, Theo H ^b   Sudaryo, Mondastri K ^a   Mathoera, Rejiv B ^a   Van Den Heuvel, Marry M ^a   Al Doray, Abdel Alim M ^c   Nijman, Rien M ^a   Van Steenbrugge, Gert J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P27;

ARTICLE; BLASTEMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; NEPHROBLASTOMA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROLIFERATION INDEX; PROTEIN EXPRESSION; STROMA CELL; TUMOR GROWTH;

ADOLESCENT; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; KIDNEY; KIDNEY NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; WILMS TUMOR;

EID: 0842311614     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0884-02     Document Type: Article

References (43)

1. Besckwith, J. B. Renal neoplasms of childhood. In: S. S. Sternberg (ed.), Diagnostic Surgical Pathology, pp. 1741-1766. New York: Raven Press, 1994.
2. Wiliams, J. A., Champion, J., Douglass, E. C., Parham, D., Hammond, E., and Webber, B. Relapsed Wilms' tumor, factors affecting survival and cure. Am. J. Clin. Oncol., 8: 324-328, 1985.
3. Wen, J. G., van Steenbrugge, G. J., Egeler, R. M., and Nijman Rien, M. Progress of fundamental research in Wilms' tumor. Urol. Res., 25: 223-230, 1997.
4. Barbareschi, M., Girlando, S., Mauri, F. M., Forti, S., Eccher, C., Mauri, F. A., Togni, R., Dalla Palma, P., and Doglioni, C. Quantitative growth fraction evaluation with MIBI and Ki67 antibodies in breast carcinomas. Am. J. Clin. Pathol., 102: 171-175, 1994.
5. De Riese, W. T., Crabtree, W., Allhoff, E., Werner, M., Liedke, S., Lenis, G., Atzpodien, J., and Kirchner, H. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J. Clin. Oncol., 11: 1804-1808, 1993.
6. Gerdes, J., Schwab, U., Lemke, H., and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13-20, 1983.
7. Youssef, E. M., Matsuda, T., Takada, N., Osugi, H., Higashino, M., Kinoshita, H., Watanabe, T., Katsura, Y., Wanibuchi, H., and Fukushima, S. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the oesophagus. Cancer (Phila.), 76: 358-366, 1995.
8. Cattoretti, G., Becker, M. H., Key, G., Duchrow, M., Schluter, C., Galle, J., and Gerdes, J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168: 357-363, 1992.
9. Benjamin, D. R. Proliferating cell nuclear antigen (PCNA) and paediatric tumours: assessment of proliferative activity. Pediatr. Pathol., 11: 507-519, 1991.
10. Khine, M. M., Aung, W., Sibbons, P. D., Howard, C. V., Clapham, E., McGill, F., and Van Veilzen, D. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIBI-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index. Lab. Investig., 70: 125-129, 1994.
11. Delahunt, B., Farrant, G. J., Bethwaite, P. B., Nacey, J. N., and Lewis, M. E. Assessment of proliferative activity in Wilms' tumor. Anal. Cell. Pathol., 7: 127-138, 1994.
12. Kip1 for restriction point control of the fibroblast cell cycle. Science (Wash. DC), 272: 877-880, 1996.
13. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
14. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-65, 1994.
15. Sanchez-Beato, M., Saez, A. I., Martinz-Montero, J. C., Maeto, M. S., Sanchez-Verde, L., Villuendas, R., Troncone, G., and Piris, M. A. Cyclin-dependent kinase inhibitor p27Kip1 in lymphoid tissue: p27Kip1 expression in inversely proportional to the proliferative index. Am. J. Pathol., 151: 151-160, 1997.
16. Kip1 in prostatic adenocarcinoma. Mod. Pathol., 11: 324-328, 1998.
17. Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. Anticancer Res., 18: 3991-3996, 1998.
18. Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am. J. Pathol., 153: 305-312, 1998.
19. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
20. Kip1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am. J. Pathol., 154: 119-225, 1999.
21. kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
22. 1a, b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.
23. De Riese, W., Allhoff, E., Werner, M., Atzpodien, J., Kirchner, H., Stief, C. G., Djamilian, M., Schlick, R., and Jonas, U. Proliferative behaviour and cytogenetic changes in human renal-cell carcinoma. World J. Urol., 9: 79-85, 1991.
24. Boccon-Gibod, L. Pathological evaluation of renal tumors in children: International Society of Pediatric Oncology approach. Ped. Dev. Pathol., 1: 243-248, 1998.
25. Rose, D. S., Maddox, P. H., and Brown, D. C. Which proliferation markers for routine immunohistology? A comparison of five antibodies. J. Clin. Pathol. (Lond.), 47: 1010-1014, 1994.
26. Hall, P. A., Richards, M. A., Gregory, W. M., d'Ardenne, A. J., Lister, T. A., and Stansfeld, A. G. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J. Pathol., 154: 223-235, 1988.
27. Simony, J., Pujol, J. L., Radal, M., Ursule, E., Michel, F. B., and Pujol, H. In situ evaluation of growth fractions determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res., 50: 4382-4387, 1990.
28. Brown, D. C., Cole, D., Gatter, K. C., and Mason, D. Y. Carcinoma of the cervix uteri: an assessment of tumor proliferation using the monoclonal antibody Ki-67. Br. J. Cancer, 57: 178-181, 1988.
29. Shyr, Y. M., Su, C. H., Li, A. F., Wu, C. W., and Lui, W. Y. The role of MIB-1 index in the prognosis of resectable pancreatic head cancer. Hepatogastroentrology, 46: 2968-2973, 1999.
30. Keshgegian, A. A., Johnston, E., and Canaan, A. Bc-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am. J. Clin. Pathol., 110: 443-449, 1998.
31. Mierau, G. W., and Beckwith, J. B. Ultrastructure and histogenesis of the renal tumours of childhood: an overview. Ultrastruct. Pathol., 11: 313-333, 1987.
32. Porschen, R., Classen, S., Piontek, M., and Borchard, F. Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Res., 54: 587-591, 1994.
33. Kip1. Nat. Med., 3: 152-154, 1997.
34. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugimachi, K., and Akiyoshi, T. p27 expression and gastric carcinoma. Nat. Med., 3: 593, 1997.
35. Singh, S. P., Lipman, J., Goldman, H., Ellis, F. H., Aizenman, L., Cangi, M. G., Signoretti, S., Chiaur, D. S., Pagano, M., and Loda, M. loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res., 58: 1730-1735, 1998.
36. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., and Giordano, G. G. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small lung cancer. Cancer Res., 57: 3381-3385, 1997.
37. Yang, R. M., Naitoh, J., Murphy, M. J., Wang, H. J., Philipson, J., Dekernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
38. Vis, A. N., Noordzij, M. A., Fitoz, K., Wildhagen, M. F., Schroder, F. H., and van der Kwast, T. H. Prognostic value of cell-cycle proteins p27kip1, MIB-1, and the cell-adhesion protein CD44s in surgically treated patients with prostate cancer. J. Urol., 164: 2156-2161, 2000.
39. Vis, A. N., van Rhijn, B. W. G., Noordzij, M. A., Schroder, F. H., and van der Kwast, T. H. Value of tissue markers p27 Kip-1, MIB-1, and CD44s for the pre-operative prediction of tumor features in screen detected prostate cancer. J. Pathol., 197: 148-154, 2002.
40. Kip1 in multistage colorectal carcinogenesis. Cancer Res., 58: 114-122, 1998.
41. Kip1. Cancer Res., 56: 1389-1399, 1996.
42. Jordan, R. C., Bradley, G., and Slingerland, J. Reduced levels of the cell-cycle inhibitor p27(kip1) in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol., 152: 585-590, 1998.
43. kip1 expression in endocrine and other tumors. Am. J. Pathol., 150: 401-407, 1997.